Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: Martin Spallone who wrote (86)	1/27/1998 11:15:00 PM
From: Joel	Read Replies (1) \| Respond to of 586

IMHO the conference call was upbeat with a conserative overtone. I am very pleased with the clinical testing procedures and expected revenues that the Prosorba Column will ultimately produce. It was stated by Dr. Blank that the device was good and safe. A conservative estimate of revenues was $240M to $480M by treating only the most severe cases of RA ie. 5 to 10% of the RA population in the U.S. The larger market potential has not yet been identified ( use of the column for other diseases) such as Lupus, MS and others. The real potential of this company is on the horizon and I expect the stock price to continue to move higher as new developments are announced. The road will be rocky, however long term holders will be richly rewarded. While talking to their PR firm yesterday they indicated that new announcements will be scheduled on an ongoing basis over the next few weeks. The purpose is raise the awarness level of this relatively unknown company. They intend to raise the name recognition and potential. Lets hope they do a good job. Joel